Medipower: Do the 16-asset portfolio and the 7-asset deal actually improve returns after financing
Based on the disclosed numbers, both acquisition moves still clear the post-interest test, but not with the same comfort. The 16-asset portfolio keeps a more reasonable spread, while the 7-asset deal already leaves a much thinner gap between property yield and debt cost.
What This Follow-Up Is Isolating
The main article argued that Medipower’s 2026 story is not just about portfolio size, but about the quality of growth. This follow-up stops one layer earlier than the shareholder question and asks something more basic: do the new acquisitions actually leave excess return after financing costs.
That matters because the two sides of the equation are not equally firm. On the income side, Medipower is disclosing representative NOI, meaning underwriting-style property income rather than a full period of owned operating history under Medipower. On the financing side, at least for part of the pipeline, debt terms are already concrete. So the spread has to be read cautiously: the cost of debt is fairly visible, while the yield side still has to be executed.
The gap between the two transactions already shows up in the first line. The 16-asset portfolio carries representative NOI of about $19.9 million on a price of about $276 million, which implies a property yield of about 7.2%. The 7-asset deal carries representative NOI of about $7.5 million on a $115 million purchase price, or only about 6.5%. That is still positive, but much less generous against the debt cost that has been disclosed.
| Deal | Price / cost | Disclosed NOI | Disclosed occupancy | Implied property yield |
|---|---|---|---|---|
| 16-asset portfolio | About $276 million | About $19.9 million | About 96% | About 7.2% |
| 7-asset deal | About $115 million | About $7.5 million | About 99.6% to 100% | About 6.5% |
| Springfield | About $37.5 million | About $2.63 million | About 99% | About 7.0% |
The chart above uses 5.33% as a conservative hurdle for the 16-asset portfolio because that is the financing cost disclosed for the first five completed assets. The sixth asset inside the same portfolio came with assumed debt at a fixed 3.38%, so the real average cost on the first six closings is actually somewhat better. That is the core point: the 16-asset portfolio still looks like a transaction with room after financing. The 7-asset deal already starts with a much thinner cushion.
The 16-Asset Portfolio: There Is Room After Financing, But Part Of It Comes From A Friendly Starting Structure
In the 16-asset portfolio, the company disclosed a price of about $276 million and representative NOI of about $19.9 million. That produces a property yield of about 7.2%, which looks reasonable for a levered open-air shopping-center transaction.
But the more interesting part is the move from theory to execution. In the annual report, the deal was still framed around an intention to finance about 65% of the consideration through loans and to fund the rest through own sources plus the Phoenix partnership. After the balance-sheet date, six out of the sixteen assets were already closed, and Medipower then disclosed actual financing terms for the first time: five assets were financed at about 64% of cost with fixed-rate debt at 5.33% for seven years, with the first three years carrying interest-only payments. A sixth asset was financed through an assumed loan at about 57% of cost, at a fixed 3.38% rate with a 30-year amortization schedule.
That is encouraging, but not perfectly clean. Encouraging, because it means the debt that has actually been closed so far costs less than the representative NOI yield. Not perfectly clean, because part of the comfort in the early years also comes from grace on principal. In other words, the post-financing return does look positive, but part of the ease comes from debt structure, not only from asset yield.
In a simplified test, if the 16-asset portfolio is modeled at the disclosed $276 million price, roughly 65% debt, and a 5.33% financing cost, annual interest expense comes out at roughly $9.6 million. Against representative NOI of $19.9 million, that leaves about $10.3 million before principal, corporate overhead, tax, and other costs. Using the roughly $110 million equity package disclosed for the partnership, that translates into something around a 9% to 10% pre-principal return. If the real average financing cost ends up closer to the mix already disclosed on the first six closings, the figure improves somewhat.
This chart is not a profit forecast. It is only a stress test of the spread: how much of representative NOI remains after the cost of debt, before principal, corporate costs, taxes, additional transaction costs, or any operating slippage. On that basis, the 16-asset portfolio still looks like a transaction with room.
There is another nuance that is easy to miss. The disclosed occupancy on the 16-asset portfolio is about 96%, not 100%. That means Medipower is not buying only a static rent stream. It is also buying some operational upside. That matters because it gives one more layer of support above the financing spread. But it also reminds the reader that the $19.9 million is still representative NOI, not NOI that Medipower has already earned through a full owned period.
The 7-Asset Deal: The Numbers Are Positive, But There Is Not Much Room For Error
The 7-asset deal looks very different. The disclosed price is $115 million, representative NOI is about $7.5 million, and disclosed occupancy ranges from 99.6% in the annual report to full occupancy in the February immediate report. That produces a property yield of only about 6.5%.
The same immediate report also disclosed the expected financing terms: about 62% of the acquisition cost through loans from two financial institutions, for five years, at an average annual rate of 5.17%, with one of the loans carrying two and a half years of interest-only payments. At that point the spread between property yield and debt cost is already meaningfully compressed. The gap between representative NOI yield and the interest rate is only about 135 basis points.
Translated into dollars, that implies expected debt of about $71.3 million and annual interest expense of about $3.7 million. Against representative NOI of $7.5 million, only about $3.8 million remains before principal, overhead, tax, and other costs. On the roughly $44 million equity layer disclosed in the annual report, that is still a positive pre-principal return of roughly 8.7%, but it is already a return that is much more sensitive to even small slippage.
There is also a subtler point here. The 7-asset portfolio is already almost full. That sounds reassuring, but it also means it is harder to count on a quick operational lift to widen the spread. Unlike the 16-asset portfolio, where there is still some room for occupancy improvement, the 7-asset case has to lean much more heavily on stability and on Medipower’s ability to “maximize rental potential” without paying for that through extra capital spending, commercial concessions, or weaker occupancy.
Another factor that softens the picture is the debt structure itself. One of the two loans in the 7-asset deal is expected to enjoy two and a half years of interest-only payments. So even if the deal does contribute after financing, part of the early contribution will be helped by timing, not only by operating economics.
Springfield Is The Litmus Test For Medipower’s Growth Style
The only asset that was actually closed during 2025 and already offers a cleaner benchmark is Springfield. The company bought it for about $37.5 million, with adjusted annual NOI of about $2.63 million, which implies a property yield of about 7.0%, and financed about 62.5% of cost at a fixed 6% rate.
The message from Springfield is straightforward: even the deal that has already closed works with a positive spread, but not a fat one, of roughly one percentage point between property yield and debt cost. This is not a story of buying assets at double-digit yields with cheap funding. It is a story of buying relatively stable assets at positive but not large spreads, in the hope that the combination of operating stability, selective improvement, and tolerable financing terms will create excess return.
In that sense, Springfield actually reinforces the cautious read on the 7-asset deal. That transaction is not some obvious outlier on the upside compared with what the company already showed. It extends the same pattern, where the spread exists but requires discipline. And it also supports the relatively better read on the 16-asset portfolio, because there the opening yield is higher and the financing already disclosed on the first six assets does not look suffocating.
What Still Has To Happen For This Test To Truly Pass
First: representative NOI has to turn into actual NOI under Medipower. That sounds trivial, but it is not the same thing. In both the 16-asset and 7-asset transactions, the company is still relying here on representative deal numbers rather than a full year of owned results.
Second: the remaining 10 assets in the large portfolio need to close on financing terms similar to those already disclosed. If the debt cost rises or the leverage level falls materially, equity returns compress.
Third: the 7-asset deal has to enter the Phoenix framework without another deterioration in economics. Phoenix solves the equity-capacity problem, but it does not widen the spread between property yield and debt cost. If the underlying spread is already narrow, even a strong equity partner will not automatically turn it into a fat-return transaction.
Fourth: in 2026 the market needs to see not just acquisition closings, but real improvement in FFO and AFFO after financing expense. Otherwise Medipower will be left with a bigger portfolio story, not necessarily a better-return story.
Bottom Line
Based on what has been disclosed so far, the answer is yes, but with two very clear caveats.
The 16-asset portfolio passes the post-financing return test more comfortably. The representative property yield looks high enough to absorb the debt cost already disclosed on the first six assets, and there is still some operational room above 96% occupancy. The 7-asset deal also passes that test, but with much less comfort. There the spread against the interest rate is already thin, and part of the help in the early years comes from interest-only debt structure.
So the right way to read Medipower in 2026 is not “more assets automatically mean better returns.” The right reading is more precise: the 16-asset portfolio has a reasonable chance of improving returns after financing, while the 7-asset deal looks helpful but far thinner. If debt terms remain similar and representative NOI proves out in actual operations, both moves can help. If either of those conditions breaks, the 7-asset transaction is likely to be the first place where the spread starts to feel too tight.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.